NTLA vs NVCT

Intellia Therapeutics, Inc. vs Nuvectis Pharma, Inc. — Valuation Comparison 2026

NTLA

Biotechnology
Intellia Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$13.68
Last close
Models
9/13
Active
VS

NVCT

Biotechnology
Nuvectis Pharma, Inc.
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$10.19
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NTLA Fair ValueNTLA Upside NVCT Fair ValueNVCT Upside
Bayesian DCF Intrinsic $4.02 -70.6% $3.24 -68.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.55 -95.5%
Dynamic NAV Asset-Based $6.80 -50.3% $1.15 -88.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NTLA vs NVCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NTLA vs NVCT — Which Stock Is More Undervalued?

NTLA scores higher with a 6.5/10 quality rating vs NVCT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intellia Therapeutics, Inc. (NTLA) and Nuvectis Pharma, Inc. (NVCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NTLA currently trades at $13.68 with a QOC of 6.5/10, while NVCT trades at $10.19 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).